The impact of dialysate flow rate on haemodialysis adequacy: a systematic review and meta-analysis.

Autor: Iman Y; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada., Bamforth R; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada., Ewhrudjakpor R; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada., Komenda P; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada.; Quanta Dialysis Technologies, Alcester, UK.; University of Manitoba, Rady Faculty of Health Sciences, Department of Internal Medicine, Winnipeg, Manitoba, Canada., Gorbe K; Quanta Dialysis Technologies, Alcester, UK., Whitlock R; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada., Bohm C; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada.; University of Manitoba, Rady Faculty of Health Sciences, Department of Internal Medicine, Winnipeg, Manitoba, Canada., Tangri N; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada.; University of Manitoba, Rady Faculty of Health Sciences, Department of Internal Medicine, Winnipeg, Manitoba, Canada., Collister D; Seven Oaks Hospital Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada.; University of Manitoba, Rady Faculty of Health Sciences, Department of Internal Medicine, Winnipeg, Manitoba, Canada.; University of Alberta, Faculty of Medicine & Dentistry, Department of Medicine, Edmonton, Alberta, Canada.
Jazyk: angličtina
Zdroj: Clinical kidney journal [Clin Kidney J] 2024 Jun 04; Vol. 17 (7), pp. sfae163. Date of Electronic Publication: 2024 Jun 04 (Print Publication: 2024).
DOI: 10.1093/ckj/sfae163
Abstrakt: Background: Patients with kidney failure treated with maintenance haemodialysis (HD) require appropriate small molecule clearance. Historically, a component of measuring 'dialysis adequacy' has been quantified using urea kinetic modelling that is dependent on the HD prescription. However, the impact of dialysate flow rate on urea clearance remains poorly described in vivo and its influence on other patient-important outcomes of adequacy is uncertain.
Methods: We searched Embase, MEDLINE and the Cochrane Library from inception until April 2022 for randomized controlled trials and observational trials comparing a higher dialysate flow rate (800 ml/min) and lower dialysate flow rate (300 ml/min) with a standard dialysis flow rate (500 ml/min) in adults (age ≥18 years) treated with maintenance HD (>90 consecutive days). We conducted a random effects meta-analysis to estimate the pooled mean difference in dialysis adequacy as measured by Kt/V or urea reduction ratio (URR).
Results: A total of 3118 studies were identified. Of those, nine met eligibility criteria and four were included in the meta-analysis. A higher dialysate flow rate (800 ml/min) increased single-pool Kt/V by 0.08 [95% confidence interval (CI) 0.05-0.10, P  < .00001] and URR by 3.38 (95% CI 1.97-4.78, P  < .00001) compared with a dialysate flow rate of 500 ml/min. Clinically relevant outcomes including symptoms, cognition, physical function and mortality were lacking and studies were generally at a moderate risk of bias due to issues with randomization sequence generation, allocation concealment and blinding.
Conclusion: A higher dialysate flow increased urea-based markers of dialysis adequacy. Additional high-quality research is needed to determine the clinical, economic and environmental impacts of higher dialysate flow rates.
Competing Interests: P.K. is a consultant to Quanta Dialysis Technologies. C.B. has an ownership interest in Precision Advanced Digital Manufacturing. N.T. has equity in Quanta Dialysis Technologies and reports grants from Tricida, AstraZeneca, Janssen, Boehringer Ingelheim/Eli Lilly, Bayer, the Canadian Institutes for Health Research and the Kidney Foundation of Canada; personal fees from Tricida, AstraZeneca, Janssen, Boehringer Ingelheim/Eli Lilly, Bayer, Otsuka, Renibus, Roche, ClinPredict and Klinrisk; and other payments from ClinPredict, Klinrisk, Tricida and PulseData. ClinPredict and Klinrisk are engaged in efforts to develop and implement models for CKD progression in health systems. D.C. is funded by a KRESCENT New Investigator Award. Y.I., R.B., R.E., K.G. and R.W. report no conflicts of interest.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje